Zacks Investment Research
31 Jul 2026, 18:20 UTC · 11w ago
Amgen Q2 Earnings Preview: Will the Beat Streak Continue?
Impact · against what's priced in
The outlook for Amgen is mixed, as expected earnings beats and growth in newer products are balanced against known patent expirations for Prolia and Xgeva. The news is largely consistent with current market expectations for the company's product transition.
- AMGN+0.10
No priced-in read yet
- In context
While volume growth in Repatha and Tezspire is positive, the expected earnings beat is offset by the structural loss of patent exclusivity for Prolia and Xgeva.
Read from the article alone
